FDA of­fers Pfiz­er pri­or­i­ty re­view for tafamidis; Clar­i­vate to merge with Churchill Cap­i­tal

→ The FDA is giv­ing Pfiz­er’s tafamidis a quick look over in ad­vance of a like­ly ap­proval. The agency will give the drug a pri­or­i­ty re­view for transthyretin amy­loid car­diomy­opa­thy — of­fer­ing to lop months off the process. Of course, that pre­sumes the FDA will be back in busi­ness soon. 

→ Clar­i­vate An­a­lyt­ics is merg­ing with Churchill Cap­i­tal. The com­bined com­pa­ny will have an en­ter­prise val­ue of $4.2 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER